Prescribing information

 

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar + Mekinist is the first and only targeted treatment available for patients with BRAF V600-positive metastatic NSCLC1,2

 

Image of Cosentyx logo

is a proven, first-line treatment for patients with BRAF+ V600 mutation3

Find out more

Image of Cosentyx logo

has a well established safety
profile1,2

Find out more

dosing

offers convenient oral dosing1,2
  

Find out more

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics
  2. Mekinist (trametinib) Summary of Product Characteristics.
  3. Planchard D, et al. Lancet Oncol 2017;18:1307–1316.
Rate this content: 
No votes yet
UK | August 2021 | 118587
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com